Key result
Exosomes emerge as key cell-free mediators replicating cell therapy benefits in heart failure.
Why the study?
Exosomes have emerged as key mediators of cell therapy benefits, but their role relative to cells as therapeutic agents remains unclear.
Answers are grounded in this paper and cite their sources.
Exosomes represent a promising, highly stable cell-free alternative to whole-cell therapy for structural heart disease regeneration, bypassing the limitations of handling fragile living cells.
Mechanistic exploration has pinpointed nanosized extracellular vesicles, known as exosomes, as key mediators of the benefits of cell therapy. Exosomes appear to recapitulate the benefits of cells, and more. As durable azoic entities, exosomes have numerous practical and conceptual advantages over cells. Will cells end up just being used to manufacture exosomes, or will they find lasting value as primary therapeutic agents? Here, a venerable natural process—the generation of honey—serves as an instructive parable. Flowers make nectar, which bees collect and process into honey. Cells make conditioned media, which laboratory workers collect and process into exosomes. Unlike flowers, honey is durable, compact and nutritious, but these facts do not negate the value of flowers themselves. The parallels suggest new ways of thinking about next-generation therapeutics.
No takes yet. Share an insight, caveat, or question.
Eduardo Marbán (2018) conducted a review in Heart Failure. Exosomes was evaluated. Exosomes are emerging as key cell-free mediators of the therapeutic benefits previously attributed to cell therapy in heart failure, offering numerous practical advantages.
Synapse has enriched 10 related papers. Consider them for comparative context: